{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hiltonol+Poly-ICLC-adjuvant",
    "query": {
      "intervention": "Hiltonol Poly-ICLC-adjuvant"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 53,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hiltonol+Poly-ICLC-adjuvant&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T19:09:09.556Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07430202",
      "title": "A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))"
      ],
      "interventions": [
        {
          "name": "DNAJB1-PRKACA Peptide Vaccine",
          "type": "DRUG"
        },
        {
          "name": "DRP-104",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2026-09",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07430202"
    },
    {
      "nct_id": "NCT01094496",
      "title": "A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The \"N-ABLE\" Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "CDX-1307 Vaccine Regimen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2010-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2020-02-13",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094496"
    },
    {
      "nct_id": "NCT02134925",
      "title": "Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Adenoma",
        "Colorectal Carcinoma",
        "Colorectal Conventional Adenoma With Severe Dysplasia",
        "Colorectal Tubulovillous Adenoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "MUC1 Peptide-Poly-ICLC Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 110,
      "start_date": "2014-06-23",
      "completion_date": "2027-03-09",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Kansas City, Missouri + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02134925"
    },
    {
      "nct_id": "NCT01846143",
      "title": "Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "pBCAR3-phosphopeptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pIRS2-phosphopeptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2013-05",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-08-12",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846143"
    },
    {
      "nct_id": "NCT06963697",
      "title": "Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Personalized Synthetic Long Peptide Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jaime Leandro Foundation for Therapeutic Cancer Vaccines",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06963697"
    },
    {
      "nct_id": "NCT01810016",
      "title": "NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unresectable or Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NY-ESO-1 Protein Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NY-ESO-1 OLP4 Vaccine with Poly-ICLC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2014-01-24",
      "completion_date": "2016-05-17",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 4,
      "location_summary": "New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01810016"
    },
    {
      "nct_id": "NCT05013216",
      "title": "Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Risk Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cohort A: Patients at high risk of developing pancreatic cancer.",
          "type": "DRUG"
        },
        {
          "name": "Cohort B: Patients must have evidence of a pancreatic cystic neoplasm",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2022-04-11",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05013216"
    },
    {
      "nct_id": "NCT06218303",
      "title": "Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ductal Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "MUC1 Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiltonol®",
          "type": "DRUG"
        },
        {
          "name": "Aromatase Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Selective estrogen receptor modulator (SERM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Finn, Olivera, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2024-02-07",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06218303"
    },
    {
      "nct_id": "NCT00773097",
      "title": "Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Risk for Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "MUC1 - Poly ICLC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Robert Schoen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 46,
      "start_date": "2008-10",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2019-01-07",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00773097"
    },
    {
      "nct_id": "NCT06782932",
      "title": "Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "AGEN2373",
          "type": "DRUG"
        },
        {
          "name": "Balstilimab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "GVAX",
          "type": "DRUG"
        },
        {
          "name": "AGEN2373 (RP2D)",
          "type": "DRUG"
        },
        {
          "name": "mKRASvax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2025-05-27",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-09-24T19:09:09.556Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06782932"
    }
  ]
}